Inhibition of experimentally induced mouse prostatic hyperplasia by castration or steroid antagonist administration
- PMID: 1696141
- DOI: 10.1095/biolreprod43.2.353
Inhibition of experimentally induced mouse prostatic hyperplasia by castration or steroid antagonist administration
Abstract
Mouse prostatic hyperplasia has been induced experimentally by implanting fetal urogenital sinus tissue into the prostate gland of syngeneic mice. We compared the effects of castration and steroid antagonist administration on the growth of the prostate gland during both the early (15 days) and late (30 days) phases of prostatic enlargement. Castration at the time of induction of prostatic hyperplasia is by far the most effective method of inhibiting prostatic overgrowth. A comparison of castration for 7 days with the short-term (7 days) administration of steroid antagonists showed that during the early phase of prostatic enlargement castration is more effective than antiandrogen, which is more effective than 5 alpha-reductase inhibitors. In the late phase of mouse prostatic enlargement, castration for 7 days is less effective than treatment with either antiandrogen or a 5 alpha-reductase inhibitor. Our data indicate that treatment with a combination of an antiestrogen (keoxifene) with a 5 alpha-reductase inhibitor (in particular, 6-methylene progesterone) is the most effective combination for reducing prostatic overgrowth. The antiestrogen (keoxifene) treatment alone was ineffective in both the early and late phases of prostatic overgrowth.
Similar articles
-
Effect of 5-alpha-reductase inhibition and dexamethasone administration on the growth characteristics and intratumor androgen levels of the human prostate cancer cell line PC-3.Prostate. 1994 May;24(5):229-36. doi: 10.1002/pros.2990240503. Prostate. 1994. PMID: 8170835
-
Tissue interactions and prostatic growth. I. Induction of adult mouse prostatic hyperplasia by fetal urogenital sinus implants.Biol Reprod. 1984 Aug;31(1):155-63. doi: 10.1095/biolreprod31.1.155. Biol Reprod. 1984. PMID: 6205700
-
Characterization of fetal urogenital sinus-induced prostatic hyperplasia in the mouse: time course, hormonal requirement, age dependency, and responsiveness of various adult organs to growth induction by fetal urogenital sinus tissues.Biol Reprod. 1988 Aug;39(1):50-7. doi: 10.1095/biolreprod39.1.50. Biol Reprod. 1988. PMID: 2462918
-
Pathogenesis and medical treatment of benign prostatic hyperplasia.Prostate Suppl. 1989;2:95-104. doi: 10.1002/pros.2990150510. Prostate Suppl. 1989. PMID: 2482776 Review.
-
Overview of benign prostatic hypertrophy.Urology. 1989 Oct;34(4 Suppl):57-63; discussion 87-96. doi: 10.1016/0090-4295(89)90235-5. Urology. 1989. PMID: 2477935 Review.
Cited by
-
Estrogenic action of commonly used fragrant agent citral induces prostatic hyperplasia.Urol Res. 1992;20(2):139-44. doi: 10.1007/BF00296526. Urol Res. 1992. PMID: 1372772
-
Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing.J Vis Exp. 2019 Aug 14;(150):10.3791/59802. doi: 10.3791/59802. J Vis Exp. 2019. PMID: 31475976 Free PMC article.
-
Fibroblasts are critical determinants in prostatic cancer growth and dissemination.Cancer Metastasis Rev. 1991 Oct;10(3):263-74. doi: 10.1007/BF00050797. Cancer Metastasis Rev. 1991. PMID: 1722435 Review.
-
Inhibitory Effect of Yongdamsagan-Tang Water Extract, a Traditional Herbal Formula, on Testosterone-Induced Benign Prostatic Hyperplasia in Rats.Evid Based Complement Alternat Med. 2016;2016:1428923. doi: 10.1155/2016/1428923. Epub 2016 Jul 18. Evid Based Complement Alternat Med. 2016. PMID: 27504137 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical